MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/jcm15145701

Медицинская библиотека · Journal of clinical medicine · 2026

Functional and Structural Outcomes of Photodynamic Therapy (PDT) With or Without Eplerenone for Central Serous Chorioretinopathy.

Gregori Giulia, Centini Chiara, Mangoni Lorenzo, Muzi Alessio, Fruttini Daniela, Quarta Alberto, Ruggeri Maria Ludovica, Rizzo Clara, Bongiovanni Giacomo, Mastropasqua Rodolfo, Mariotti Cesare, Lupidi Marco

СтатьяПеревод в очереди

Аннотация

Background/

Objectives

To evaluate whether the combination of oral eplerenone and half-dose full-fluence photodynamic therapy (HD-FF PDT) provides greater efficacy than HD-FF PDT alone in persistent central serous chorioretinopathy (CSCR).

Methods

This monocentric, retrospective, observational study included patients with persistent (>6 months) simple or complex CSCR who had previously undergone either half-dose full-fluence photodynamic therapy (HD-FF PDT) alone or HD-FF PDT combined with oral eplerenone as part of routine clinical practice between September 2024 and March 2025. Functional and morphological data collected at baseline and at 1, 3, and 6 months after treatment were retrospectively reviewed. An artificial intelligence-based algorithm was used to analyze OCT scans, quantifying subretinal and intraretinal fluid volumes (SRFV, IRFV) and assessing ellipsoid zone and external limiting membrane integrity, hyperreflective foci, subfoveal choroidal thickness (SCT), and central macular thickness (CMT).

Results

Fifty patients (53 eyes; mean age 52 years) were included, with no significant baseline differences between groups. Best-corrected visual acuity improved more significantly in Group B at 1 and 6 months (p = 0.032 and p = 0.009, respectively). At 6 months, subretinal fluid volume (SRFV), quantified by AI-based OCT analysis, was significantly lower in the combined therapy group (p = 0.014). An AI-defined complete resolution of subretinal fluid (SRFV < 0.010 mm3) was achieved more frequently in Group B than in Group A (77% vs. 22%, p = 0.001).

Conclusions

Although HD-FF PDT remains the standard treatment for persistent CSCR, adjunctive therapy with the mineralocorticoid receptor antagonist eplerenone may enhance subretinal fluid reabsorption and improve mid-term anatomical and functional outcomes.

Для цитирования: Gregori Giulia, Centini Chiara, Mangoni Lorenzo, Muzi Alessio, Fruttini Daniela, Quarta Alberto, Ruggeri Maria Ludovica, Rizzo Clara, Bongiovanni Giacomo, Mastropasqua Rodolfo, Mariotti Cesare, Lupidi Marco. Functional and Structural Outcomes of Photodynamic Therapy (PDT) With or Without Eplerenone for Central Serous Chorioretinopathy.. Journal of clinical medicine. 2026. DOI: 10.3390/jcm15145701.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.